
Sales of Novo Nordisk’s diabetes drugs including Ozempic slow sharply | Pharmaceuticals industry
Sales of Novo Nordisk’s injectable diabetes drugs including Ozempic have slowed sharply amid fierce

Sales of Novo Nordisk’s injectable diabetes drugs including Ozempic have slowed sharply amid fierce

Denmark’s Novo Nordisk has cut its annual revenue and profit forecasts after disappointingly “flabby”